Zolmitriptan Nasal Spray in the Acute Treatment of Cluster Headache: A Meta‐Analysis of Two Studies

Hedlund, Cecilia; Rapoport, Alan M.; Dodick, David W.; Goadsby, Peter J.

doi:10.1111/j.1526-4610.2009.01518.x

Cited by 34 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent review of medical treatments for cluster headache (Tyagi 2009) identified the same studies involving triptans as this review, but did not carry out any meta-analyses, while a meta-analysis of the two included studies of intranasal zolmitriptan (Hedlund 2009) is in agreement with findings in this review. A recent Cochrane review of oxygen therapy for migraine and cluster headache (Bennett 2008), found weak evidence for efficacy of normobaric oxygen therapy in treating acute cluster headache based on 19 participants in a double blind cross-over study comparing oxygen therapy and air, and 50 participants in an open cross-over study comparing oxygen therapy with ergotamine tartrate.…”

Section: Agreements and Disagreements With Other Studies Or Reviewssupporting

confidence: 53%

Triptans for acute cluster headache

Law¹,

Derry²,

Moore³

2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Section: Agreements and Disagreements With Other Studies Or Reviewssupporting

confidence: 53%

Triptans for acute cluster headache

Law¹,

Derry²,

Moore³

2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

“…There is generally little reporting of effect size and its precision, which was only presented in seven abstracts [17, 26, 34, 36–38, 45]. Effect size (active minus control) in percentages or absolute value, with 95% confidence intervals (CI), is the clinically relevant measure.…”

Section: Commentsmentioning

confidence: 99%

CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache

Tfelt‐Hansen

2011

J Headache Pain

View full text Add to dashboard Cite

A CONSORT statement on the content of abstracts of randomised, controlled trials (RCTs) was published in 2008. I therefore reviewed the abstracts from 2009 to 2010 published on RCTs in Cephalalgia, Headache and other (non-headache) journals. The following items were reviewed: number of patients, reporting of response either in percentages or absolute values, the use of p values, and effect size with its precision. The latter was recommended in the CONSORT statement. A total of 46 abstracts were reviewed and effect size with 95% confidence intervals was only reported in seven abstracts. The influence of the CONSORT statement on reporting in abstracts has so far only had a limited influence on the headache literature.

show abstract

“…Since expression data on all individual subjects was available for the outcome of risk of breast cancer, we also conducted individual patient data (IPD) meta-analysis [16]. For this we used the clustered unconditional logistic regression analyses [16,17] with disease status as a dichotomous dependent variable, comparison-specific z-scores as the predictor variable and comparison indicator as the clustering variable. Comparison-specific z-scores were estimated as the relative deviates (mean expression/standard deviation of expression) within each comparison group.…”

Section: Methodsmentioning

confidence: 99%

Association of HADHA expression with the risk of breast cancer: targeted subset analysis and meta-analysis of microarray data

Mamtani

Kulkarni

2012

BMC Res Notes

View full text Add to dashboard Cite

BackgroundThe role of n-3 fatty acids in prevention of breast cancer is well recognized, but the underlying molecular mechanisms are still unclear. In view of the growing need for early detection of breast cancer, Graham et al. (2010) studied the microarray gene expression in histologically normal epithelium of subjects with or without breast cancer. We conducted a secondary analysis of this dataset with a focus on the genes (n = 47) involved in fat and lipid metabolism. We used stepwise multivariate logistic regression analyses, volcano plots and false discovery rates for association analyses. We also conducted meta-analyses of other microarray studies using random effects models for three outcomes--risk of breast cancer (380 breast cancer patients and 240 normal subjects), risk of metastasis (430 metastatic compared to 1104 non-metastatic breast cancers) and risk of recurrence (484 recurring versus 890 non-recurring breast cancers).ResultsThe HADHA gene [hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit] was significantly under-expressed in breast cancer; more so in those with estrogen receptor-negative status. Our meta-analysis showed an 18.4%-26% reduction in HADHA expression in breast cancer. Also, there was an inconclusive but consistent under-expression of HADHA in subjects with metastatic and recurring breast cancers.ConclusionsInvolvement of mitochondria and the mitochondrial trifunctional protein (encoded by HADHA gene) in breast carcinogenesis is known. Our results lend additional support to the possibility of this involvement. Further, our results suggest that targeted subset analysis of large genome-based datasets can provide interesting association signals.

show abstract

Zolmitriptan Nasal Spray in the Acute Treatment of Cluster Headache: A Meta‐Analysis of Two Studies

Abstract: Zolmitriptan nasal spray at a dose of 5 mg and 10 mg is efficacious in the acute treatment of episodic and chronic cluster headache.

Cited by 34 publications

References 19 publications

Triptans for acute cluster headache

Triptans for acute cluster headache

CONSORT recommendations in abstracts of randomised, controlled trials on migraine and headache

Association of HADHA expression with the risk of breast cancer: targeted subset analysis and meta-analysis of microarray data

Contact Info

Product

Resources

About